In the present systematic review and meta-analysis, the use of corticosteroids increased mortality, ICU LOS, and the rate of secondary infection in patients with influenza pneumonia but did not influence MV days.
Our analysis demonstrates that corticosteroids not only increase mortality but also prolong ICU LOS. There are several potential mechanisms that could underlie the higher mortality and ICU LOS observed in patients who received corticosteroids. First, corticosteroids reduce systemic inflammation [23]. Once attacked by the virus, the immune system is activated [24]. Corticosteroids inhibit immune reactions by suppressing inflammatory reactions, preventing the migration of inflammatory cells from the circulation to issues by suppressing the synthesis of chemokines and cytokines, and inhibiting immune responses mediated by T cells and B cells [25, 26]. Thus, the alterations in immune reactions caused by corticosteroids might lead to prolonged virus viremia and delay viral clearance, ultimately increasing the risk of mortality [6, 27]. One of our included studies showed that patients who received corticosteroids had lower procalcitonin levels (0.5 vs 0.7 ng/mL, P = 0.02) [20], while another showed that the patients who died had a higher rate of immunosuppression (34.7% vs. 15.1%, P = 0.02) [13]. Second, our analysis found that patients who received corticosteroids were more likely to develop secondary bacterial pneumonia due to immunosuppression. In addition, longer ICU LOS has also been shown to contribute to secondary infection [28]. Third, due to immune-suppressing effects of corticosteroids, the risk of developing critical illness is increased in corticosteroid-treated patients [29]. One study found that the rate of shock was 8% in the corticosteroid group and 4.4% in the control group [19]. In addition, the invasive MV rate was also increased by corticosteroids, at 38.4% in the corticosteroid group and 4.5% in the control group [19]. Fourth, other corticosteroid-related adverse outcomes, such as cardiovascular events, including fluid retention, premature atherosclerotic disease, and arrhythmias, also increased mortality in patients with influenza pneumonia [30,31,32]. In the included studies, patients who used more vasopressors had higher mortality [13]. Thus, the above mechanisms may contribute to why patients with influenza pneumonia had higher mortality.
We also performed a subgroup analysis according to viral types. In all types of influenza virus, mortality was higher in those treated with corticosteroids than in controls, although symptoms were more rapidly progressive patients and the risk of ARDS higher in patients infected with H7N9 [1, 2]. Moreover, we included more large sample studies than were included in previous meta-analyses related to influenza [33]. In addition, we focused only on patients with influenza pneumonia and not on those infected with influenza alone or those with influenza who were admitted to the ICU. Influenza pneumonia has been shown to be related to life-threatening respiratory failure and mortality [34]; however, not all patients infected with influenza develop influenza pneumonia. In the present study, we tried to determine whether patients who develop influenza pneumonia benefit from corticosteroids. Nevertheless, we may have omitted patients with influenza pneumonia who were included in trials that studied all influenza patients, and this may have influenced the final results of our analysis.
Studies exploring the effects of corticosteroids on patients with community-based pneumonia have produced positive results [6]. The main reason for these findings is that those infected by bacteria benefit from corticosteroids when given appropriate antibiotic therapy. The early use of antiviral therapy could also reduce mortality. Seven studies reported the use of antiviral therapy. On the one hand, we did not explore the exact role of antiviral therapy in the effects of corticosteroids due to a lack of raw data. On the other hand, we also only included patients who developed influenza pneumonia, which resulted in the included cases being more severe than those included in studies in which patients using antiviral therapy were included.
Moreover, patients who received corticosteroids were more likely to have a superinfection, such as secondary bacterial pneumonia or invasive fungal infection, and exacerbation of underlying conditions, and they also had more prolonged ICU LOS than was found in the no-corticosteroid group [35]. In addition, one study showed that the use of corticosteroids delayed the initiation of neuraminidase inhibitors, with ICU LOS longer in patients who did not receive neuraminidase inhibitors within 5 days of illness [18].
In terms of MV days, corticosteroids did not seem to make a difference. However, only three studies in our analysis reported data on MV days, and the insignificant results might therefore be due to the fact that we had such a small sample size. In other words, a type II error might have occurred because of the limited number of patients.
Other than the aforementioned reasons, the effects of corticosteroids could also be influenced by the following three factors. First, the condition of the respiratory system could be responsible. Corticosteroids can provide benefits to patients with an oxygenation index (OI; partial arterial pressure of oxygen/fraction of inspired oxygen) < 300, but it may also increase the 60-day mortality rate in those with OI > 300 [19]. Second, the time of corticosteroid initiation could be a contributing factor. Compared with no treatment, administration within the first 3 days was more strongly associated with an increased risk of death [13, 36]. Moreover, corticosteroids are beneficial if used early after ARDS onset but otherwise increase mortality. In reality, however, some patients received corticosteroids after ARDS onset, which offset the negative effect of corticosteroids on mortality [37]. Third, the dose of corticosteroids may affect results. High doses of corticosteroids have been associated with greater mortality and a longer duration of viral shedding [15]. In Li’s study, mortality was twice as high in patients who received a high dose of corticosteroids than in those who received a low-moderate dose [19]. The initial dose of corticosteroids varied among our included studies, and some of them did not report related information. Additionally, due to the study design, not all patients in one study received a unified dose of corticosteroids. Moreover, studies have shown that corticosteroids are usually initiated when shock is non-responsive to fluids and vasopressors. Thus, patients who receive corticosteroids tend to have more severe disease, as evidenced by their higher APACHE II scores [36]. It is therefore unclear whether their increased risk of mortality is directly associated with corticosteroid use or due to the severity of disease. None of the studies included in our analysis was a randomized controlled study (RCT). Because the influencing factors could not be controlled, our analysis was highly heterogeneous. This might explain why corticosteroids did not make a difference in some studies.
Despite these findings, the limitations of our study should be addressed. First, the applicability of our study results is limited because none of the studies included in our analysis was an RCT. Second, only two studies reported the dose of corticosteroids and the duration of it use. Third, the baseline characteristics of the patients can influence outcomes and varied among the studies included in our analysis. For example, younger age and fewer underlying diseases might be associated with fewer secondary infections [38]. Finally, the effect of corticosteroids on patients with influenza pneumonia remains controversial. Previous studies that showed a negative effect for corticosteroids may have influenced how the clinicians used corticosteroids in our included studies. Finally, there may have been selection bias because none of the studies included was an RCT.